e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Pathobiology of pulmonary vascular diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats
L. Savale, O. Sitbon, A. Houssaini, D. Rideau, A. Perrin, S. Eddahibi, S. Adnot (Creteil, Clamart, France)
Source:
Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Session:
Pathobiology of pulmonary vascular diseases
Session type:
E-Communication Session
Number:
4326
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Savale, O. Sitbon, A. Houssaini, D. Rideau, A. Perrin, S. Eddahibi, S. Adnot (Creteil, Clamart, France). Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 2009; 34: Suppl. 53, 4326
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
BOGAARD Harm - 15.09.2009 14:33
very interesting work!
Any idea whether the protease inhibitors have effects on pulmonary microvascular endothelial cells?
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 20s
Year: 2003
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Year: 2012
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016
Year: 2017
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
Source: Eur Respir J 2013; 42: 869-870
Year: 2013
Pharmacological inhibition of carbonic anhydrases 9 and 12 attenuates monocrotaline-induced pulmonary hypertension in rats
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept